Renal

Ibraghimov-Beskrovnaya O, Bukanov N. 2008. Polycystic kidney diseases: From molecular discoveries to targeted therapeutic strategies. Cell Mol Life Sci 65:605-619.

Natoli TA, Gareski TC, Dackowski WR, Smith L, Bukanov N, Russo RJ, Husson H, Matthews D, Piepenhagen PA, Ibraghimov-Beskrovnaya O. 2008. Pkd1 and Nek8 mutations affect cell-cell adhesion and cilia in cysts formed in kidney organ cultures. Am J Physiol Renal Physiol 294:F73-83.

El Chaar M, Chen J, Seshan SV, Jha S, Richardson I, Ledbetter SR, Vaughan JED, Poppas DP, Felsen D. 2007. Effect of combination therapy with enalapril and the TGF-beta antagonist 1D11 in unilateral ureteral obstruction. Amer J of Physiology 292:F1291-1301.

Fountain KJ, Kloss A, Garibyan I, Blitshteyn B, Brezzani A, Kyostio-Moore S, Zuk A, Sacchiero R, Cohen AS. 2007. Analysis of creatinine in mouse and rat serum by ion exchange high performance liquid chromatography for in vivo studies of renal function. J Chromatogr B Analyt Technol Biomed Life Sci 846:245-251.

Ibraghimov-Beskrovnaya O. 2007. Molecular pathogenesis of ADPKD and development of targeted therapeutic options. Nephrol Dial Transplant 22:3367-3370.

Ibraghimov-Beskrovnaya O. 2007. Targeting dysregulated cell cycle and apoptosis for polycystic kidney disease therapy. Cell Cycle 6:776-779.

Kent PS. 2007. Issues of obesity in kidney transplant. J Ren Nutr 17:107-113.

Möller CC, Wei C, Altintas MM, Li J, Greka A, Ohse T, Pippin JW, Rastaldi MP, Wawersik S, Schiavi S, Henger A, Kretzler M, Shankland SJ, Reiser J. 2007. Induction of TRPC6 channel in acquired forms of proteinuric kidney disease. J Am Soc Nephrol 18:29-36.

Benigni A, Zoja C, Campana M, Corna D, Sangalli F, Rottoli D, Gagliardini E, Conti S, Ledbetter S, Remuzzi G. 2006. Beneficial effect of TGFbeta antagonism in treating diabetic nephropathy depends on when treatment is started. Nephron - Exper Nephrol 104:e158-168.

Berndt TJ, Bielesz B, Craig TA, Tebben PJ, Bacic D, Wagner CA, O'Brien S, Schiavi S, Biber J, Murer H, Kumar R. 2006. Secreted frizzled-related protein-4 reduces sodium-phosphate co-transporter abundance and activity in proximal tubule cells. Pflugers Arch 451:579-587.

Bukanov NO, Smith LA, Klinger KW, Ledbetter S, Ibraghimov-Beskrovnaya O. 2006. Long-lasting arrest of murine polycystic kidney disease with CDK inhibitor roscovitine. Nature 444:949-952.

Duggal A, Hanus M, Zhorov E, Dagher R, Plone MA, Goldberg J, Burke SK. 2006. Novel dosage forms and regimens for sevelamer-based phosphate binders. J Ren Nutr 16:248-252.

Ibraghimov-Beskrovnaya O, Bukanov NO. 2006. In vitro cystogenesis: The search for drugs antagonizing cyst development. Nephrol. Ther. 2:S109-114.

Mak GZ, Kavanaugh GM, Buschmann MM, Stickley SM, Koch M, Goss KH, Waechter H, Zuk A, Matlin KS. 2006. Regulated synthesis and functions of Laminin 5 in polarized Madin-Darby canine kidney epithelial cells. Mol Biol Cell 17:3664-3677.

Pande S, Ritter CS, Rothstein M, Wiesen K, Vassiliadis J, Kumar R, Schiavi SC, Slatapolsky E, Brown AJ. 2006. FGF-23 and sFRP-4 in Chronic Kidney Disease and post-renal transplantation. Nephron Physiol 104:23-32.

Schiavi SC. 2006. Fibroblast growth factor 23: The making of a hormone. Kidney Int 69:425-427.

Smith LA, Bukanov NO, Husson H, Russo RJ, Barry TC, Taylor AL, Beier DR, Ibraghimov-Beskrovnaya O. 2006. Development of polycystic kidney disease in juvenile cystic kidney mice: insights into pathogenesis, ciliary abnormalities, and common features with human disease. J Am Soc Nephrol 17:2821-2831.

Syal A, Schiavi S, Chakravarty S, Dwarakanath V, Quigley R, Baum M. 2006. Fibroblast growth factor-23 increases mouse PGE2 production in vivo and in vitro. Am J Physiol Renal Physiol 290:F450-455.

Baum M, Schiavi S, Dwarakanath V, Quigley R. 2005. Effect of fibroblast growth factor-23 on phosphate transport in proximal tubules. Kidney Int 68:1148-1153.

Berndt TJ, Schiavi S, Kumar R. 2005. "Phosphatonins" and the regulation of phosphorus homeostasis. Am J Physiol Renal Physiol 289:F1170-1182.

Dahly-Vernon A, Sharma M, McCarthy E, Savin V, Ledbetter S, Roman R. 2005. Transforming growth factor-{beta}, 20-HETE interaction, and glomerular injury in Dahl salt-sensitive rats. Hypertension.

Ferramosca E, Burke S, Chasan-Taber S, Ratti C, Chertow GM, Raggi P. 2005. Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients. Am Heart J 149:820-825.

Luo Z, Akita GY, Date T, Treleaven C, Vincent KA, Woodcock D, Cheng SH, Gregory RJ, Jiang C. 2005. Adenovirus-mediated expression of beta-adrenergic receptor kinase C-terminus reduces intimal hyperplasia and luminal stenosis of arteriovenous polytetrafluoroethylene grafts in pigs. Circulation 111:1679-1684

Raggi P, James G, Burke SK, Bommer J, Chasan-Taber S, Holzer H, Braun J, Chertow GM. 2005. Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in hemodialysis. J Bone Miner Res 20:764-772.

Russo RJ, Husson H, Joly D, Bukanov NO, Patey N, Knebelmann B, Ibraghimov-Beskrovnaya O. 2005. Impaired formation of desmosomal junctions in ADPKD epithelia. Histochem Cell Biol:1-11.

Surendran K, Schiavi S, Hruska KA. 2005. Wnt-dependent {beta}-catenin signaling is activated after unilateral ureteral obstruction, and recombinant secreted frizzled-related protein 4 alters the progression of renal fibrosis. J Am Soc Nephrol 16:2373-2384.

Garg JP, Chasan-Taber S, Blair A, Plone M, Bommer J, Raggi P, Chertow GM. 2005. Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: a randomized clinical trial. Arthritis Rheum 52:290-295.

Babich V, Zeng WZ, Yeh BI, Ibraghimov-Beskrovnaya O, Cai Y, Somlo S, Huang CL. 2004. The N-terminal extracellular domain is required for polycystin-1-dependent channel activity. J Biol Chem 279:25582-25589.

Borovecki F, Jelic M, Grgurevic L, Sampath KT, Bosukonda D, Vukicevic S. 2004. Bone morphogenetic protein-7 from serum of pregnant mice is available to the fetus through placental transfer during early stages of development. Nephron Exp Nephrol 97:e26-32.

Burke SK. 2004. Arterial calcification in chronic kidney disease. Sem in Nephrol 24:403-407.

Chauvet V, Tian X, Husson H, Grimm DH, Wang T, Hiesberger T, Igarashi P, Bennett AM, Ibraghimov-Beskrovnaya O, Somlo S, Caplan MJ. 2004. Mechanical stimuli induce cleavage and nuclear translocation of the polycystin-1 C terminus. J Clin Invest 114:1433-1443.

Chertow GM, Raggi P, Chasan-Taber S, Bommer J, Holzer H, Burke SK. 2004. Determinants of progressive vascular calcification in haemodialysis patients. Nephrol Dial Transplant. 19:1489-1496.

Husson H, Manavalan P, Akmaev VR, Russo RJ, Cook B, Richards B, Barberio D, Liu D, Cao X, Landes GM, Wang CJ, Roberts BL, Klinger KW, Grubman SA, Jefferson DM, Ibraghimov-Beskrovnaya O. 2004. New insights into ADPKD molecular pathways using combination of SAGE and microarray technologies. Genomics 84:497-510.

Khanna AK, Plummer MS, Hilton G, Pieper GM, Ledbetter S. 2004. Anti-transforming growth factor antibody at low but not high doses limits cyclosporine-mediated nephrotoxicity without altering rat cardiac allograft survival: potential of therapeutic applications. Circulation 110:3822-3829.

Ma LJ, Jha S, Ling H, Pozzi A, Ledbetter S, Fogo AB. 2004. Divergent effects of low versus high dose anti-TGF-beta antibody in puromycin aminonucleoside nephropathy in rats. Kidney Int 65:106-115.

Schiavi SC, Kumar R. 2004. The phosphatonin pathway: new insights in phosphate homeostasis. Kidney Int 65:1-14.

Swearingen RA, Zhorov E, Cohen A, Sybertz T, Barry EF. 2004. Determination of the binding parameter constants of Renagel capsules and tablets at pH 7 by high performance capillary electrophoresis. J Pharma & Biomed Anal 35:753-760.

Benigni A, Zoja C, Corna D, Zatelli C, Conti S, Campana M, Gagliardini E, Rottoli D, Zanchi C, Abbate M, Ledbetter S, Remuzzi G. 2003. Add-on anti-TGF-beta antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat. J Am Soc Nephrol 14:1816-1824.

Burke SK, Dillon MA, Hemken DE, Rezabek MS, Balwit JM. 2003. Meta-analysis of the effect of sevelamer on phosphorus, calcium, PTH, and serum lipids in dialysis patients. Adv in Renal Replac Ther 10:133-145.

Chertow GM, Raggi P, McCarthy JT, Schulman G, Silberzweig J, Kuhlik A, Goodman WG, Boulay A, Burke SK, Toto RD. 2003. The effects of sevelamer and calcium acetate on proxies of atherosclerotic and arteriosclerotic vascular disease in hemodialysis patients. Am J Nephrol 23:307-314.

Cozzolino M, Staniforth ME, Liapis H, Finch J, Burke SK, Dusso AS, Slatopolsky E. 2003. Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia. Kidney Int 64:1653-1661.

Katsumata K, Kusano K, Hirata M, Tsunemi K, Nagano N, Burke SK, Fukushima N. 2003. Sevelamer hydrochloride prevents ectopic calcification and renal osteodystrophy in chronic renal failure rats. Kidney Int 64:441-450.

Ling H, Li X, Jha S, Wang W, Karetskaya L, Pratt B, Ledbetter S. 2003. Therapeutic role of TGF-beta-neutralizing antibody in mouse cyclosporin A nephropathy: morphologic improvement associated with functional preservation. J Am Soc Nephrol 14:377-388.

Nagano N, Miyata S, Obana S, Kobayashi N, Fukushima N, Burke SK, Wada M. 2003. Sevelamer hydrochloride, a phosphate binder, protects against deterioration of renal function in rats with progressive chronic renal insufficiency. Nephrol Dial Transplant 18:2014-2023.

Streets AJ, Newby LJ, O'Hare MJ, Bukanov NO, Ibraghimov-Beskrovnaya O, Ong AC. 2003. Functional analysis of PKD1 transgenic lines reveals a direct role for polycystin-1 in mediating cell-cell adhesion. J Am Soc Nephrol 14:1804-1815.

Jiang Y, Zhang W, Kondo K, Klco JM, St Martin TB, Dufault MR, Madden SL, Kaelin WG, Jr., Nacht M. 2003. Gene expression profiling in a renal cell carcinoma cell line: dissecting VHL and hypoxia-dependent pathways. Mol Cancer Res 1:453-462.

Amin N. 2002. The impact of improved phosphorus control: use of sevelamer hydrochloride in patients with chronic renal failure. Nephrol Dial Transplant 17:340-345.

Braunlin W, Zhorov E, Guo A, Apruzzese W, Xu Q, Hook P, Smisek DL, Mandeville WH, Holmes-Farley SR. 2002. Bile acid binding to sevelamer HCl. Kidney Int 62:611-619.

Bukanov NO, Husson H, Dackowski WR, Lawrence BD, Clow PA, Roberts BL, Klinger KW, Ibraghimov-Beskrovnaya O. 2002. Functional polycystin-1 expression is developmentally regulated during epithelial morphogenesis in vitro: downregulation and loss of membrane localization during cystogenesis. Hum Mol Genet 11:923-936.

Chertow GM, Burke SK, Raggi P. 2002. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62:245-252.

Cozzolino M, Dusso AS, Liapis H, Finch J, Lu Y, Burke SK, Slatopolsky E. 2002. The effects of sevelamer hydrochloride and calcium carbonate on kidney calcification in uremic rats. J Am Soc Nephrol 13:2299-2308.

Dackowski WR, Luderer HF, Manavalan P, Bukanov NO, Russo RJ, Roberts BL, Klinger KW, Ibraghimov-Beskrovnaya O. 2002. Canine PKD1 is a single-copy gene: genomic organization and comparative analysis. Genomics 80:105-112.

Dahly AJ, Hoagland KM, Flasch AK, Jha S, Ledbetter SR, Roman RJ. 2002. Antihypertensive effects of chronic anti-TGF-beta antibody therapy in Dahl S rats. Am J Physiol Regul Integr Comp Physiol 283:R757-767.

Plone MA, Petersen JS, Rosenbaum DP, Burke SK. 2002. Sevelamer, a phosphate-binding polymer, is a non-absorbed compound. Clin Pharmacokinet 41:517-523.

Raggi P, Boulay A, Chasan-Taber S, Amin N, Dillon M, Burke SK, Chertow GM. 2002. Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 39:695-701.

Schiavi SC, Moe OW. 2002. Phosphatonins: a new class of phosphate-regulating proteins. Curr Opin Nephrol Hypertens 11:423-430.

Swearingen RA, Chen X, Petersen JS, Riley KS, Wang D, Zhorov E. 2002. Determination of the binding parameter constants of Renagel capsules and tablets utilizing the Langmuir approximation at various pH by ion chromatography. J Pharm Biomed Anal 29:195-201.

Bowe AE, Finnegan R, Jan de Beur SM, Cho J, Levine MA, Kumar R, Schiavi SC. 2001. FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate. Biochem & Biophys Res Commun 284:977-981.

Burke SK, Amin NS, Incerti C, Plone MA, Lee JW. 2001. Sevelamer hydrochloride (Renagel), a phosphate-binding polymer, does not alter the pharmacokinetics of two commonly used antihypertensives in healthy volunteers. J Clin Pharmacol 41:199-205.

Burke S, Amin N, Incerti C, Plone M, Watson N. 2001. Sevelamer hydrochloride (Renagel), a nonabsorbed phosphate-binding polymer, does not interfere with digoxin or warfarin pharmacokinetics. J Clin Pharmacol 41:193-198.

Nagano N, Miyata S, Obana S, Eto N, Fukushima N, Burke SK, Wada M. 2001. Renal mineral handling in normal rats treated with sevelamer hydrochloride (Renagel), a noncalcemic phosphate binder. Nephron 89:321-328.

Nagano N, Miyata S, Obana S, Ozai M, Kobayashi N, Fukushima N, Burke SK, Wada M. 2001. Sevelamer hydrochloride (Renagel), a non-calcaemic phosphate binder, arrests parathyroid gland hyperplasia in rats with progressive chronic renal insufficiency. Nephrol Dial Transplant 16:1870-1878.